Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 7, 2004. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests related to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes and director disclosures.
- Shares Repurchased: 1,000,000 Ordinary shares of 25 pence each.
- Repurchase Date: December 6, 2004.
- Price per Share: 1,133.15 pence.
- Treasury Shares Held: 60,748,000 (post-transaction).
- Shares in Issue: 5,876,260,396 (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,000,000 shares for Treasury. Additionally, the GlaxoSmithKline US Retirement Savings Plan saw an increase in Ordinary Share ADRs from 18,804,786 to 18,841,944 due to fund movements on December 3, 2004, at an average price of $43.73.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 1,000,000 share repurchase (1,000,000 shares x 1,133.15 pence).
- Confirm the updated total share count excluding Treasury shares (5,876,260,396).
- Note that Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the US Retirement Savings Plan shares.
- Recognize that this filing does not contain operational financial results for the period.